About
Mitchell H. Finer Ph.D. (Mitch) joined MPM Capital as Managing Director in 2015 and is a member of the board of directors of MPM portfolio company Semma Therapeutics. For three decades Mitch has focused in the areas of regenerative medicine, cancer immunotherapy and cell and gene therapy, helping to advance products from conception through phase III clinical programs. Prior to MPM, Mitch served as CSO of bluebird bio, where he was responsible for strategic build of bluebird’s gene therapy business and led the strategic development of the LentiGlobin product from preclinical research through demonstration of long-term therapeutic benefit and safety in beta-thalassemia patients. Mitch continues to serve on bluebird bio’s scientific advisory board. Prior to bluebird, Mitch has served as CEO of Intracel Corporation and Genteric Inc, and as VP Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi). Mitch also successfully co-founded retinal disease gene thera
Position in the VCSift Database
- • 3 investors at ElevateBio are tracked.
- • 22 investors hold the Chief Scientific Officer role in VCSift. Mitchell Finer is one of them.
- • 491 investors are based in Cambridge, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Cambridge, US
Contact Information
Find more investors like Mitchell
Search Investors